Fluent Financial LLC boosted its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 4.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 94,502 shares of the pharmaceutical company’s stock after acquiring an additional 3,658 shares during the period. GlaxoSmithKline comprises 2.1% of Fluent Financial LLC’s portfolio, making the stock its 15th largest holding. Fluent Financial LLC’s holdings in GlaxoSmithKline were worth $3,557,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of GSK. Milestone Advisory Partners acquired a new position in shares of GlaxoSmithKline in the second quarter valued at approximately $25,000. Creative Financial Designs Inc. ADV acquired a new position in shares of GlaxoSmithKline in the second quarter valued at approximately $31,000. Manchester Financial Inc. raised its position in shares of GlaxoSmithKline by 382.4% in the second quarter. Manchester Financial Inc. now owns 820 shares of the pharmaceutical company’s stock valued at $33,000 after buying an additional 650 shares during the last quarter. MV Capital Management Inc. acquired a new position in shares of GlaxoSmithKline in the second quarter valued at approximately $33,000. Finally, Beese Fulmer Investment Management Inc. acquired a new position in shares of GlaxoSmithKline in the second quarter valued at approximately $34,000. 12.12% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have recently weighed in on GSK shares. Societe Generale reissued a “buy” rating on shares of GlaxoSmithKline in a research report on Friday, September 18th. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating and set a $41.00 target price for the company. in a report on Tuesday, September 15th. Credit Suisse Group restated a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, October 5th. UBS Group restated a “buy” rating on shares of GlaxoSmithKline in a report on Monday, October 12th. Finally, Oddo Bhf upgraded shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating in a report on Wednesday, September 23rd. Four analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. GlaxoSmithKline presently has an average rating of “Hold” and an average price target of $41.00.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 29th. The pharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.01). GlaxoSmithKline had a return on equity of 31.21% and a net margin of 19.03%. The business had revenue of $9.46 billion for the quarter, compared to analysts’ expectations of $9.60 billion. Analysts forecast that GlaxoSmithKline plc will post 3.01 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were paid a dividend of $0.4914 per share. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.47. This represents a $1.97 annualized dividend and a yield of 5.38%. The ex-dividend date of this dividend was Thursday, August 13th. GlaxoSmithKline’s payout ratio is currently 61.20%.
In other GlaxoSmithKline news, Director Plc Glaxosmithkline acquired 361,111 shares of the firm’s stock in a transaction on Tuesday, July 21st. The stock was bought at an average cost of $18.00 per share, for a total transaction of $6,499,998.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.00% of the stock is owned by insiders.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: What is a management fee?
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.